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Abstract
Introduction
Streptococcus pneumoniae is the commonest cause of bacteremic pneumonia among HIV-
infected persons. As more countries with high HIV prevalence are implementing infant pneu-
mococcal conjugate vaccine (PCV) programs, we aimed to describe the baseline clinical
characteristics of adult invasive pneumococcal disease (IPD) in the pre-PCV era in South
Africa in order to interpret potential indirect effects following vaccine use.
Methods
National, active, laboratory-based surveillance for IPD was conducted in South Africa from
1 January 2003 through 31 December 2008. At 25 enhanced surveillance (ES) hospital
sites, clinical data, including HIV serostatus, were collected from IPD patients 5 years of
age. We compared the clinical characteristics of individuals with IPD in those HIV-infected
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and -uninfected using multivariable analysis. PCV was introduced into the routine South
African Expanded Program on Immunization (EPI) in 2009.
Results
In South Africa, from 2003–2008, 17 604 cases of IPD occurred amongst persons 5 years
of age, with an average incidence of 7 cases per 100 000 person-years. Against a national
HIV-prevalence of 18%, 89% (4190/4734) of IPD patients from ES sites were HIV-infected.
IPD incidence in HIV-infected individuals is 43 times higher than in HIV-uninfected persons
(52 per 100 000 vs. 1.2 per 100 000), with a peak in the HIV-infected elderly population of
237 per 100 000 persons. Most HIV-infected individuals presented with bacteremia (74%,
3 091/4 190). HIV-uninfected individuals were older; and had more chronic conditions
(excluding HIV) than HIV-infected persons (39% (210/544) vs. 19% (790/4190), p<0.001).
During the pre-PCV immunization era in South Africa, 71% of serotypes amongst HIV-
infected persons were covered by PCV13 vs. 73% amongst HIV-uninfected persons, p =
0.4, OR 0.9 (CI 0.7–1.1).
Conclusion
Seventy to eighty-five percent of adult IPD in the pre-PCV era were vaccine serotypes and
93% of cases had recognized risk factors (including HIV-infection) for pneumococcal vacci-
nation. These data describe the epidemiology of IPD amongst HIV-infected and -uninfected
adults during the pre-PCV era and provide a robust baseline to calculate the indirect effect
of PCV in future studies.
Introduction
Streptococcus pneumoniae is the most common cause of bacteremia and bacterial pneumonia
among HIV-infected persons, and has been shown to occur between 30 and 100 times more
frequently in HIV-infected than HIV-uninfected individuals.[1–4] Recurrent disease is seen
more frequently with HIV infection, with approximately 25% of patients having a recurrence
within 12 months.[1, 5, 6]
This study was conducted in South Africa, which reports a HIV prevalence of 18% amongst
adults in 2008.[7] In population groups with a high HIV prevalence the epidemiological pat-
tern of invasive pneumococcal disease (IPD) seems to change, with a peak seen in the young
adult population as well as the typical but more marked peaks seen in the infant and elderly
population groups.[4, 6, 8] Despite the higher rate of IPD in HIV-infected individuals the
majority of studies have not shown higher case-fatality ratios amongst people co-infected with
HIV.[1, 3, 6]
Some differences in IPD epidemiology have been described in HIV-infected versus HIV-
uninfected individuals. Firstly, HIV-infected adults tend to be infected more commonly with
pneumococcal serotypes that are typically seen in young children, and in relation to this, HIV-
infected people tend to have a higher proportion of penicillin non-susceptible isolates.[3, 9–12]
In contrast, serotype 1 disease tends to be proportionally less common amongst HIV-infected
than HIV-uninfected persons.[3, 4, 13] Besides HIV as a stand-alone risk factor, HIV-infected
individuals with IPD tend to have less underlying disease than HIV-uninfected individuals.
[14]
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Use of the polysaccharide pneumococcal vaccine (PPV23) in HIV-infected African adults is
controversial.[5] However, studies using the 7-valent pneumococcal conjugate vaccine (PCV7)
are promising, showing a 74% vaccine efficacy against vaccine serotypes in HIV-infected adults
with a previous episode of IPD, albeit with subsequent waning of immunity.[15] Some coun-
tries, including South Africa, have already shown an indirect effect in the adult population fol-
lowing infant PCV immunization.[16–18] In South Africa and the United States of America,
this decrease was seen in both HIV-infected (-25 to -59% for vaccine serotypes attributed to
childhood PCV immunization) and HIV-uninfected adults (-52 to -86% for vaccine serotypes).
[18, 19]
Reporting baseline clinical characteristics of IPD amongst adults in a setting with high HIV
prevalence is important to elicit the indirect and long-term effects, including serotype replace-
ment, of PCV introduction on IPD in adult populations. In this analysis we aimed to describe
the baseline epidemiology of IPD in the pre-PCV era amongst HIV-infected and -uninfected
persons 5 years of age using data derived from national surveillance.
Methods
GERMS-SA conducts national, active laboratory-based surveillance across South Africa in a
network consisting of approximately 130 public and private microbiology laboratories. Each
laboratory is responsible for sending S. pneumoniae isolates, along with demographic details of
the patient to a reference laboratory (the Centre for Respiratory Diseases and Meningitis
(CRDM) at the National Institute for Communicable Diseases (NICD)) where confirmatory
tests, serotyping and antimicrobial susceptibility testing are performed. Data from individuals
diagnosed with IPD from 1 January 2003 through to 31 December 2008 were included in this
analysis. From 2003 to 2005 our surveillance network strengthened and remained relatively
stable thereafter. For this reason trends in incidence by serotype were only examined from
2005 onwards. Comprehensive audits of cases identified but not reported were conducted for
all the public laboratories: unreported cases ranged from 16% to 21% over the 6 years and their
demographic data were included in our database.[20] PCV7 was introduced into the South
African EPI in 2009, and replaced by PCV13 in 2011. There was minimal use of either PCV7
or PPV23 during the study period.
IPD was defined as identification of S. pneumoniae from any usually sterile site (cerebrospi-
nal fluid (CSF), blood, pleural fluid, joint fluid, ascitic fluid, vitreous fluid, etc.). Multiple iso-
lates of S. pneumoniae identified from the same person were counted as one case provided they
occurred within 21 days of the first isolate. S. pneumoniae were identified by either: culture of
the organism, consistent Gram stain plus detection of S. pneumoniae antigen by latex aggluti-
nation, or detection of S. pneumoniae by direct PCR (polymerase chain reaction) of the speci-
men. Antimicrobial disc diffusion susceptibility testing of potentially resistant strains was
confirmed by broth microdilution. Antimicrobial susceptibility was reported as susceptible or
non-susceptible (intermediate and resistant isolates) based on the Clinical and Laboratory
Standards Institute (CLSI) interpretive criteria.[21] Serotyping of viable organisms were deter-
mined using the Quellung reaction (Statens Serum Institut, Copenhagen, Denmark). Serotypes
were grouped according to those covered by PCV13 (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A,
19F and 23F) and PPV23 vaccines (1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F,
18C, 19A, 19F, 20, 22F, 23F, 33F and serotype 6A cross-protection was assumed). When calcu-
lating incidence of individual serotypes we assumed the age-specific proportion of serotypes
with non-viable or missing pneumococcal isolates to be that of those with available isolates and
imputed serotype data for 5 041 cases.
HIV Infection and Adult Pneumococcal Disease in the Prevaccine Era
PLOS ONE | DOI:10.1371/journal.pone.0149104 February 10, 2016 3 / 17
Enhanced surveillance (ES) was conducted at 25 sentinel-hospital sites situated in all 9
provinces of South Africa. Where available, consenting persons with IPD (or their legal guard-
ians) were interviewed using a standardized questionnaire. Clinical details were retrieved
from medical record review performed on cases of IPD at these hospitals. As clinical details
were only available from patients presenting to ES sites, a comparison of cases from enhanced
versus non-enhanced surveillance sites was done to show representativeness of data from the
ES sites.
The following demographic and clinical details were collected from each person under sur-
veillance: age/ date of birth, sex and specimen type (CSF, blood, other for any other specimen
from a sterile site). Additional details were collected at ES sites: clinical syndrome (meningitis,
bacteremic pneumonia, bacteremia without focus, other), Pitt bacteremia score for severity of
illness (score 0 for mild, 1–3 for moderate, 4–12 for severe illness),[22] HIV status, in-hospital
outcome and any underlying condition predisposing to IPD. Predisposing conditions were fur-
ther classified into ACIP (Advisory Committee on Immunization Practices) conditions (asple-
nia/ sickle cell disease; chronic lung, renal, liver or cardiac condition; diabetes; solid organ
transplant; immunotherapy; malignancy; primary immunodeficiency; CSF leak following a
head injury; alcohol dependency; tobacco use) and other risk factors (cerebrovascular accident;
burns).[23] Demographic, laboratory and clinical details for each patient were linked using Epi
Info, version 6.04d, and later updated to Access.
Incidence of IPD was calculated using South African population denominators from Statis-
tics-South Africa.[24] HIV-specific incidence rates for South Africa were calculated by assum-
ing that the proportion of patients who tested positive for HIV at sentinel sites was the same in
those who were not tested. HIV population denominators for 2008 were obtained from the
Thembisa model 1.7 version 3.[25]
Statistical analysis was done using Stata version 11 (StataCorp Inc., College Station, Texas,
USA) and p-values of0.05 were considered significant throughout. Trends in incidence rates
by age-category and serotype were calculated using Poisson regression. Univariate analysis of
characteristics associated with IPD among HIV-infected and HIV-uninfected persons was per-
formed using Fisher’s exact test or the Mantel–Haenszel χ2-test for categorical variables. Multi-
variable logistic regression models were evaluated comparing IPD cases at enhanced and non-
enhanced surveillance sites, and comparing IPD cases amongst those HIV-infected and–unin-
fected. We started with all variables that were significant at p-value less than 0.05 on univariate
analysis, and dropped non-significant factors with stepwise backward selection. All two-way
interactions were evaluated.
Ethical clearance and permission to conduct laboratory-based and enhanced surveillance
in South Africa for this study was obtained from the Health Research Ethics Committee
(Human), University of Witwatersrand (Clearance number M02-10-42); the University of
Stellenbosch Health Research Ethics Committee (Reference number N04/01/0021), the
National Institute for Communicable Diseases Research Committee (Clearance number
M060449); and the South African Department of Health (Reference H2/12/8). The following
consent procedures were approved by the above mentioned ethics committees: Written con-
sent was obtained from all patients (or parents/legal guardians of minors) at ES sites, prior to
being interviewed, for participation in the ES program. Patients from ES sites who had
already been discharged from hospital were interviewed telephonically and gave verbal con-
sent, documented by surveillance officers on the written consent forms. Parents/ legal guard-
ians of minors gave written consent (or verbal if the child had already been discharged from
hospital) on behalf of their children <18 years of age. Patients from ES sites who were unable
to provide written or verbal consent (due to severity of illness, death or lost to follow up)
were still included in the study and their clinical data were collected only through medical
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record review. Participants not consenting to answer the enhanced surveillance questionnaire
were still included in the laboratory-based surveillance program. All patient identifiers were
removed prior to data analysis.
Results
Surveillance Population
From 2003 through 2008, 27 632 individuals with IPD were reported to GERMS-SA surveil-
lance. Ninety-five percent (26 278) had known age, and 17 604 (67%) of these were aged 5
years and older. Antimicrobial susceptibility testing and serotyping were performed on 71%
(12 563/17 604) of the isolates. Forty-eight percent of individuals (8 468/17 604) were from ES
sites. Medical records were found for 82% (6 960/8 468) of cases at ES sites and data on HIV-
serostatus were available for 68% (4 734) of these individuals. (Fig 1)
Incidence of invasive pneumococcal disease
Incidence of IPD occurring in persons 5 years of age increased from 2003–2005, then
remained relatively stable (7.4 to 7.3 per 100 000 population, p = 0.27; 95% CI 0.98–1.00) from
2005–2008. A small decrease in incidence was seen in the 5–19 year age group from 2005–2008
(3.4 to 3 per 100 000 population, p = 0.004, 95% CI 0.91–0.98). (Fig 2)
In 2008, the relative risk of IPD amongst HIV-infected individuals was 43 times greater
than HIV-uninfected individuals (52 per 100 000 vs. 1.2 per 100 000, respectively). (Table 1)
For HIV-uninfected individuals, incidence increased with increasing age, with a peak in
those 65 years (4.1 per 100 000). (Fig 3a) However, in HIV-infected individuals incidence
followed a U-shaped curve with peaks in the later childhood and elderly age categories
(81.4 in 5–19 years; 46.3 in 20–49 years; 74.7 in 50–64 years; 237.2 in65 years). (Fig 3b;
Table 1)
Descriptive epidemiology
IPD was more common amongst females (53%, 9 096/17 375, gender unknown for 229 cases).
Age ranged from 5 years through to 103 years (median 33 years, IQR 25–43). S. pneumoniae
was cultured from CSF in 35% (6 128/17 604) of patients and from blood in 54% (9 537/17
604). The remaining 11% (1 939/17 604) were from either pleural fluid (1 643), peritoneal fluid
(123), joint fluid (110) or pus from a deep-seated abscesses (63).
From 2005 to 2008, antimicrobial non-susceptibility of the isolates increased significantly
for penicillin (range: 23–29% non-susceptible, MIC0.06 μg/ml (p<0.001)), erythromycin (8–
11% non-susceptible, MIC0.25 μg/ml (p<0.001)) and cotrimoxazole (41–47% non-suscepti-
ble, MIC>0.5 μg/ml (p<0.001)) but remained constant for third generation cephalosporins
(0.5% non-susceptible, MIC1.0 mg/ml (p = 0.028)).
Of 12 547 isolates serotyped (16 were non-typable), the commonest 10 serotypes included
serotypes 1, 19A, 4, 14, 23F, 6A, 6B, 3, 8 and 19F (nine of which are included in PCV13). Thir-
teen patients had a mixed serotype infection. Serotype diversity increased by increasing age
with 78% (1 732/2 223) of cases in the 5–19 year; 66% (5 563/8 443) in the 20–49 year; 65%
(868/1 328) in the 50–64 year and 61% (337/553) in the65 year age categories included in the
commonest 10 serotypes.
A significant decrease in serotype 1 disease incidence was seen during the surveillance
period (p<0.001; 1.14 to 0.7 per 100 000 population), signifying an end to a serotype 1 epi-
demic that was ongoing prior to the start of the surveillance program. Other significant
decreases once the surveillance program was properly established (2005–2008) were seen with
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serotypes 6A, 19F, 12F, 18A, 15C and 25. Serotypes 4 and 18C were the only serotypes showing
significant increases in incidence over time. (Fig 4)
Comparison of enhanced vs. non-enhanced surveillance sites
Significant differences between cases from enhanced (ES) versus non-enhanced surveillance
sites (NESS) included specimen type (25% CSF at ES vs. 44% CSF at NESS, p<0.001, Odds
Fig 1. Flow diagram of cases of invasive pneumococcal disease, South Africa, 2003–2008 (n = 27 632).
doi:10.1371/journal.pone.0149104.g001
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Ratio (OR) 0.4 (95% CI 0.3–0.4)), cotrimoxazole non-susceptibility of the isolates (47% at ES
vs. 44% at NESS, p<0.001, OR 1.1 (CI 1.1–1.2)) and percent of vaccine-preventable serotypes
(77% serotypes at ES covered by PPV23 vs. 79% at NESS, p = 0.04, OR 0.9 (CI 0.8–1)). The lat-
ter two remained significant even after controlling for specimen type. (Table 2)
Fig 2. Incidence of invasive pneumococcal disease by age category and year, South Africa, 2003–2008 (n = 17 604). Footnote: Between 2003 and
2004 there was a significant increase in disease (p<0.001), most notably in the 20–49 year age group (p<0.001), however from 2005 to 2008 disease
incidence did not change significantly overall, however a small decrease was noted in the 5–19 year age group (p = 0.004).
doi:10.1371/journal.pone.0149104.g002
Table 1. Annual incidence and relative risk of invasive pneumococcal disease amongst HIV- infected and -uninfected persons by age category,
South Africa, 2008.
Age category Invasive pneumococcal disease incidence Relative Risk (95% conﬁdence interval)
Overall (95%
conﬁdence interval)
HIV-infected (95%
conﬁdence interval)
HIV-uninfected
(95% conﬁdence
interval)
5–19yrs 3.2 (3–3.5) 81.4 (73.4–90) 0.6 (0.5–0.8) 127 (101–160)
20–49yrs 10.1 (9.7–10.5) 46.3 (44.3–48.4) 1 (0.9–1.2) 46 (40–54)
50–64yrs 7.9 (7.1–8.8) 74.7 (66.1–84.1) 2.3 (1.9–2.8) 32 (26–41)
> 65yrs 5.8 (4.9–6.9) 237.2 (171–320.7) 4.1 (3.3–5) 58 (40–83)
All ages 7.3 (7.1–7.6) 52 (50.1–54) 1.2 (1.1–1.3) 43 (39–47)
doi:10.1371/journal.pone.0149104.t001
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Fig 3. Incidence of invasive pneumococcal disease (IPD) amongst HIV-uninfected and HIV-infected persons by age category, South Africa, 2008.
doi:10.1371/journal.pone.0149104.g003
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Comparison between HIV-infected vs. HIV-uninfected individuals at ES
sites
Eighty-nine percent (4 190/4 734) of people with IPD from ESS with HIV data available were
HIV-infected and 37% (1 568/4 190) of these HIV-infected patients were newly diagnosed dur-
ing this episode of IPD.
On multivariable analysis, age between 20 and 49 years, female sex, bacteremic pneumonia
and a cotrimoxazole non-susceptible isolate were significantly more common among HIV-
infected than HIV-uninfected IPD patients. HIV-uninfected patients had better survival to dis-
charge, and more underlying conditions (apart from HIV infection) predisposing them to IPD
than HIV-infected patients. There was no difference between HIV-infected and–uninfected
adults regarding proportion of vaccine-preventable serotypes causing IPD (71% serotypes
amongst HIV-infected persons covered by PCV13 vs. 73% amongst HIV-uninfected persons,
p = 0.4, OR 0.9 (CI 0.7–1.1) and 84% serotypes amongst HIV-infected persons covered by
PPV23 vs. 86% amongst HIV-uninfected persons, p = 0.3, OR 0.9 (CI 0.6–1.1)). (Table 3)
Fig 4. Incidence of invasive pneumococcal disease among persons 5 years and older by the commonest 15 serotypes causing disease, South
Africa, 2003–2008 (n = 17 604). Footnote: * Significant changes during the established surveillance period (2005–2008) were seen in serotype 1 (p<0.001)
(down), 4 (0.02) (up), 6A (p = 0.0486) (down), 19F (p = 0.0306) (down), 12F (p = 0.0037) (down), 18C (p = 0.0368) (up). Of 17 604 cases of IPD, serotype
data were missing and thus imputed for 5 041 cases.
doi:10.1371/journal.pone.0149104.g004
HIV Infection and Adult Pneumococcal Disease in the Prevaccine Era
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Discussion
In South Africa during the pre-vaccine era, 70% of IPD in adults and older children was caused
by serotypes in PCV13 and 85% by PPV23 serotypes. IPD incidence in HIV-infected individu-
als was 43 times higher than in HIV-uninfected persons (52 per 100 000 vs.1 per 100 000), with
HIV-infected adults65 years at highest risk (IPD incidence of 237 per 100 000, 95% CI 171–
321). IPD and HIV-coinfection was associated with more bacteremia (with or without pneu-
monia) and higher in-hospital case fatality than HIV-uninfected cases.
HIV-infection is a major risk factor for IPD, with 90% of IPD amongst South African older
children and adults occurring in the 18% of South Africans who are HIV infected.[7, 24] By
2008, HAART coverage amongst HIV-infected South African adults eligible for treatment was
40% [26], this has increased to 79% in recent years.[27] Yet in South Africa, one study showed
only a 7% decrease in adult IPD attributable to the increased HAART coverage during this
same period.[18] Although HAART reduces the risk of IPD in HIV-infected persons, there
Table 2. Comparison of individuals with invasive pneumococcal disease identified at enhanced versus non-enhanced surveillance sites, South
Africa, 2003–2008 (n = 17 604).
Enhanced
sites
Non-
enhanced
sites
Univariate analysis Multivariable analysis*
n % n % Odds ratio (95% Conﬁdence interval) P-value Odds ratio (95% Conﬁdence interval) P-value
Total cases 8468 48 9136 52
Age category
5–19 years 1343 16 1609 18 Reference 0.012 Reference 0.152
20–49 years 5884 70 6171 68 1.1 (1.1–1.2) 1.1 (1–1.2)
50–64 years 886 11 983 11 1.1 (1–1.2) 1.1 (0.9–1.2)
65 years 355 4 373 4 1.1 (1–1.3) 1.0 (0.9–1.3)
Specimen type
Cerebrospinal Fluid 2106 25 4022 44 Reference <0.001
Blood 5683 67 3854 42 2.8 (2.6–3)
Other 679 8 1260 14 1 (0.9–1.1)
Antimicrobial susceptibility 6 315 6 248
Penicillin
Non-susceptible 1582 25 1 514 24 1.0 (1–1.1) 0.286
Erythromycin
Non-susceptible 639 10 641 10 1 (0.9–1.1) 0.795
Cotrimoxazole
Non-susceptible 2 983 47 2752 44 1.1 (1.1–1.2) <0.001 1.1 (1.1–1.2) <0.001
3rd Generation Cephalosporin
Non-susceptible 34 1 30 1 1.1 (0.7–1.8) 0.647
Serotypes (n = 12 563) 6 315 6 248
PCV13**
Vaccine serotypes 4 450 70 4 469 72 0.9 (0.9–1) 0.191
PPV23***
Vaccine serotypes 4 874 77 4 916 79 0.9 (0.8–1) 0.043 0.9 (0.8–1) 0.035
Footnote:
*Multivariable analysis was done including all variables with P-values <0.05 and controlling for laboratory syndrome (which accounts for specimen type
tested).
**PCV13 (Pneumococcal Conjugate Vaccine-13 valent) serotypes include: 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F.
***PPV23 (Pneumococcal Polysaccharide Vaccine-23 valent) serotypes include: 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A,
19F, 20, 22F, 23F, 33F,(6A cross protection is assumed).
doi:10.1371/journal.pone.0149104.t002
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seems to be an incomplete restoration of the immune system, necessitating additional measures
for preventing IPD in this high risk group. [28–36]
Sex, age and underlying medical conditions are established risk factors for IPD and its more
severe outcomes. [37–39] Globally IPD occurs more frequently in males than females however
we found that in persons with IPD HIV-infection was associated with female sex. In South
Africa, HIV prevalence in females is higher (11.9% in females versus 9.2% in males for 2008)
which may in part account for the disparity.[7, 40]
From age 65 years, IPD incidence in both HIV-infected and uninfected persons increases
exponentially, however in this age category the incidence amongst HIV-infected persons is 58
times higher than in HIV-uninfected individuals (237 vs. 4 cases per 100 000 population
respectively). With the rollout of ARVs, this high-risk category of elderly HIV-infected persons
is likely to grow. Similarly, there is a peak of disease in HIV-infected teenagers, which is in
stark contrast to their HIV-uninfected peers (81 vs. 0.6 cases per 100 000 population respec-
tively, relative risk of 127). Many of these HIV-infected teens are potentially long term survi-
vors of vertical HIV-transmission, with potential added risk factor of chronic lung disease,
whilst a smaller proportion may be recently infected.[41] The HIV-infected teens and elderly
are at an even higher risk with the potential development of chronic diseases which further pre-
dispose to IPD.
The highest burden of IPD in South African persons five years and older is in the young to
middle-aged adult population. The majority (88%) of disease occurred amongst HIV-infected
persons; however, 43% of HIV-uninfected persons had other underlying conditions predispos-
ing them to IPD. In our study, as seen in other studies, vaccine serotypes occur at high rates in
older children and adults, with 70% of disease caused by PCV13 serotypes and 85% by PPV23
serotypes.[3, 6, 42, 43] This was similar for both HIV-infected and uninfected individuals,
despite the individual serotype diversity seen within each group. Although South Africa follows
recommendations to vaccinate high risk individuals with PPV23 (including HIV-infected indi-
viduals), vaccine uptake is extremely low and no patient in our study had received PPV23.[44,
45]
In South Africa, we recently demonstrated an indirect effect on all serotype IPD incidence,
following PCV7 vaccination of infants, of 34% in the 25–44 year age category.[18] However,
this indirect effect was less evident amongst those in their early teens and in the elderly (>65
years) (6% reduction in 10–14 years and 14% reduction in 65+ age group)—two groups with
high incidences of IPD amongst those HIV-infected. Since 2011, PCV13 has been used in the
EPI, and it is expected that the indirect effects of PCV13 on additional serotypes will further
decrease the incidence of IPD in older children and adults. However, in HIV-infected popula-
tions additional preventative interventions could be considered such as direct vaccination of
selected groups with pneumococcal vaccine, increased uptake of the seasonal influenza vaccine
and increased use of ART.[46–49]
Previous studies in South Africa reported that HIV-coinfected persons were more likely to
be infected with penicillin non-susceptible pneumococci, however when including cotrimoxa-
zole in our multivariate model this finding fell away. Cotrimoxazole non-susceptibility
remained a significant finding in HIV-coinfected patients on multivariable analysis; this may
be due to the high use of cotrimoxazole prophylaxis in preventing opportunistic infections in
HIV-infected patients in South Africa.[50]
One important limitation of surveillance studies is that IPD incidence may be underesti-
mated.[51] Our case definition relies on the specimen taking practices of clinicians and the
health seeking behavior of the patients, which have both been found to vary greatly across our
study population.[52, 53] In many of the rural areas reporting of blood culture results are often
delayed, therefore if patients do seek medical care, clinicians often treat those with a suspected
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bacteremia empirically without laboratory investigations to confirm their diagnosis. These
cases would not have been reflected in this study and are therefore excluded from our incidence
calculations. A study during the same time period confined to a single site in South Africa with
a relatively well-defined population and adequate blood culturing practices, reported IPD inci-
dence in adults of 58 per 100 000 population.[28] Therefore the true incidence of IPD in South
African adults and older children likely lies above the 7 per 100 000 reflected here. An assump-
tion was made for 29% (5 041/17 604) of IPD isolates that distribution of serotypes by age-cate-
gory and province was similar amongst isolates that were available and those that were missing
when calculating incidence by serotype. In addition, these missing isolates could influence the
distribution of antimicrobial susceptibility data. HIV testing was not done routinely for surveil-
lance purposes and patient HIV serostatus was only available at ES sites—and only for 68% of
the patients with medical records available. Only a few parameters were available for compar-
ing cases from ES versus non-enhanced sites, and although the main differences were found in
specimen type and cotrimoxazole non-susceptibility there may be more unmeasured differ-
ences which we were unable to account for which could have influenced our model comparing
HIV-infected to HIV-uninfected patients with IPD. ASSA2003 denominators for HIV-infected
individuals tended to underestimate the number of HIV-infected individuals in the teenage
and elderly populations, therefore we used a modified version of the ASSA2003 model, Them-
bisa 1.7v3, which accounts for the survival benefits of the rollout of HAART especially amongst
the teenagers and elderly.[25, 54] This gave more plausible results for IPD incidence amongst
the teenager and elderly HIV-infected population but may still be an underestimate of true
IPD incidence.
In summary, 70–85% of adult IPD in the pre-PCV era were vaccine serotypes and 93% of
cases had recognized risk factors (including HIV-infection) for pneumococcal vaccination.
These data describe the epidemiology of IPD amongst HIV-infected and -uninfected adults
during the pre-PCV era and provide a robust baseline to calculate the indirect effect of PCV in
future studies.
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